Agilent genuttryck microarray rådata för STO-3 Agilent gene expression microarray raw data for STO-3 2021-340-1-1 https://doi.org/10.5878/3vxa-3c28 Swedish National Data Service Svensk nationell datatjänst Landing page Agilent genuttryck microarray rådata för STO-3 Agilent gene expression microarray raw data for STO-3 2021-340-1-1 https://doi.org/10.5878/3vxa-3c28 10.1002/ijc.33969 Johansson, Annelie Johansson, Annelie Lindström, Linda Lindström, Linda 2014-02057_VR 2014-02057_VR 2020-02466_VR 2020-02466_VR Swedish National Data Service Svensk nationell datatjänst Landing page Breast Neoplasms Brösttumörer Tamoxifen Tamoxifen Gene Expression Genuttryck Clinical Trial Klinisk prövning [Publikationstyp] Agilent microarray profiling of primary breast tumors in the Stockholm tamoxifen trial (STO-3) was performed in 2014. The STO-3 trial enrolled 1780 postmenopausal lymph node-negative patients with tumors smaller than or equal to 30 mm and were randomized to tamoxifen vs no endocrine therapy. Molecular analysis was possible for 808 patients with available formalin-fixed paraffin-embedded (FFPE) tissue blocks from the primary breast cancer tumor. Eighty-one patients were excluded from analysis due to insufficient invasive tumor cells, leaving 727 samples available for further analysis. Gene expression data were independently generated using custom-designed arrays, Agilent Technologies (CA, USA), containing approximately 32.1K probes, representing approximately 21.5K unique genes from FFPE breast cancer tumor tissue. 652 of 727 breast cancer tumors passed the RNA quality check according to the diagnostic quality model and were used in the analysis, of which 538 were ER-positive. The datasetet consists of a table in one (1) txt file containing: Gene expression data (Agilent custom 32K microarray) generated in 2014 for 652 primary tumors from the STO-3 trial. The variables are the 31195 probes included in the Agilent microarray used to generate the data. File name: STO3_Agilent_microarray_gMeanSignals_652.txt The 31195 probes included in the Agilent microarray used to generate the data are listed and mapped to gene names in an annotation file. Annotation file name: List_of_probes_STO3_Agilent_microarray_gMeanSignals_652.txt Agilent microarray data genererades 2014 för primära brösttumörer i den kliniska studien STO-3 för postmenopausala lymfkörtelnegativa patienter med tumörer mindre än eller lika med 30 mm. En utförligare beskrivning finns i den engelska versionen av katalogposten. Datasetet består av en tabell i en (1) txt-fil innehållande: Genuttrycksdata (Agilent custom 32K microarray) genererat år 2014 för 652 primära tumörer från STO-3 studien. Variablerna är de 31195 sonder som ingår i den Alilent microarray vilken använts för att generera datasetet. Filnamn: STO3_Agilent_microarray_gMeanSignals_652.txt De 31195 sonder som ingår i den Alilent microarray vilken använts för att generera datasetet finns listade och mappade till gen-namn i en annotationsfil. Filnamn annotationsfil: List_of_probes_STO3_Agilent_microarray_gMeanSignals_652.txt 2013 2014 Sweden Sverige Breast cancer patients diagnosed in Stockholm 1976-1990 Bröstcancerpatienter diagnostiserade i Stockholm 1976-1990 Numeric Registry extract and/or access to biobank sampleRegistry extract and/or access to biobank sample Registerutdrag och/eller tillgång till prov i biobankRegisterutdrag och/eller tillgång till prov i biobank Access to data through SND. Access to data is restricted. Åtkomst till data via SND. Tillgång till data är begränsad. restrictedAccess Johansson & Lindström et al., Clinical and Molecular Characteristics of ER-Positive Ultralow Risk Breast Cancer Tumors Identified by the 70-Gene Signature, International Journal of Cancer, 2022 Johansson & Lindström et al., Clinical and Molecular Characteristics of ER-Positive Ultralow Risk Breast Cancer Tumors Identified by the 70-Gene Signature, International Journal of Cancer, 2022 10.1002/ijc.33969 2022